Introduction: To assess the predictive value of stimulated thyroglobulin (sTg) levels before and after the first postoperative 131 I treatment in evaluating clinical outcomes in differentiated thyroid ...

(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan) in recurrent high-grade glioma (brain cancer ...

TLX101 treatment in recurrent high-grade glioma showed a median overall survival of 12.4 months, with no serious side effects reported. The study supports the potential for higher therapeutic doses of ...

In the current study, researchers from INSERM aimed to evaluate the abscopal effect potentially inducted by the use the targeted radionuclide therapy (TRT) candidate, [131I]ICF-01012, which has been ...

The agent may also be used as a companion diagnostic agent to Telix’s LAT1-targeting investigational glioblastoma therapy, TLX101 (131I-iodofalan, or 131I-IPA). TLX101 is currently being investigated ...

Like TLX101, TLX101-Tx targets the same amino acid transporter mechanism but uses therapeutic radiation for treatment. 2. 131I-TLX-101 for treatment of newly diagnosed glioblastoma (IPAX-2).

The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their ...

an anti-CD45 monoclonal antibody joined to the radioisotope Iodine-131 (131I-apamistamab) as an experimental treatment for adult acute myeloid leukemia (ClinicalTrials.gov Identifier: NCT02665065).

Therapeutic doses of 131I administered to thyrotoxic patients may cause thyroid failure. The present study used a rat model to determine thyroid function after the administration of different doses of ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...